Immunotherapy Part 2: Common Controversies |
|
Enduring |
|
$0.00 |
Immunotherapy Part 3: Common Controversies and Remaining Questions |
|
Enduring |
|
$0.00 |
Ocular Toxicities with ADCs Companion Card |
|
Enduring |
|
$0.00 |
Palliative Care Module Series - Part 2 (CE version) |
- 1.25 AMA PRA Category 1 Credit™
- 1.25 AMA PRA Category 1 Credits™- For Non-physicians
- 1.25 CNE Contact Hours
- 1.25 Participation
|
Enduring |
|
$0.00 |
SGO Taskforce for Board Certification Support Statistic Webinar Series - Part 4 |
|
Enduring |
|
$0.00 |
ERAS Guidelines: Same Day Discharge |
|
Enduring |
|
$0.00 |
Treatment Related Cardiotoxicity: Review and Management Companion Card |
|
Enduring |
|
$0.00 |
Basics of Gyn Oncology Coding On-Demand Webinar |
|
Enduring |
|
$0.00 |
Highlights from the 2024 Annual Meeting on Women's Cancer |
|
Enduring |
|
$195.00 |
Keeping up with the Chemos Series on Trastuzumab Deruxtecan ENHERTU®: Preparing to Give It (Pt. 1) |
|
Enduring |
|
$0.00 |
Keeping up with the Chemos Series on Trastuzumab Deruxtecan ENHERTU®: Administration (Pt. 2) |
|
Enduring |
|
$0.00 |
Keeping up with the Chemos Series on Trastuzumab Deruxtecan ENHERTU®: Monitoring Between Cycles (Pt. 3) |
|
Enduring |
|
$0.00 |
Molecular Target: Human Epidermal Growth Factor Receptor 2 (HER2) |
|
Enduring |
|
$0.00 |
SGO Late Breaking - FDA Approvals (2024) |
|
Enduring |
|
$0.00 |
SGO Late Breaking - SGO 2024 |
|
Enduring |
|
$0.00 |